Karyopharm Therapeutics (NASDAQ:KPTI) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below.
This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation.
View the webcast at https://app.webinar.net/pwRm6D5V8PW
Summary
Karyopharm Therapeutics reported total Q2 revenue of $33.4 million, down from $37.9 million year-over-year due to the conclusion of Menarini's reimbursement of development-related expenses.
The company is focused on selinexor's potential to treat myelofibrosis, with plans to submit an sNDA based on promising data from the SENTRY trial showing improved spleen response rates and overall survival.
Karyopharm emphasized its established hematology platform to support the commercialization of selinexor in myelofibrosis, leveraging existing infrastructure from its XPOVIO product.
Management highlighted ongoing discussions with the FDA and lenders to support their financial strategy and extend cash runway, with current liquidity expected to last until September 2026.
The company reaffirmed its 2026 revenue guidance between $130 million and $150 million and discussed strategic alternatives to address upcoming debt obligations.
Full Transcript
Richard (CEO)
In myelofibrosis. We are entering this next phase with a clear strategy, a focused organization, and an established hematology platform that positions us well for what lies ahead. With that, I'll turn the call over to Reshma, who will discuss the clinical and regulatory foundation supporting our planned submission for the first-ever combination and why we believe selinexor, as a novel therapeutic mechanism, has the potential to fundamentally change the treatment of patients with myelofibrosis.
Reshma
Thank you, Richard. As Richard discussed, we believe selinexor has the potential to fundamentally change the treatment of patients with myelofibrosis. I'd like to spend the next few minutes discussing why we believe the scientific evidence supporting that opportunity has continued to strengthen, why it supports our planned sNDA submission, and how we continue to build the clinical foundation for selinexor in myelofibrosis. Turning to Slide 10, the biological rationale for combining XPO1 and JAK inhibition is compelling.
JAK-STAT activation is a key driver of malignant clone proliferation, splenomegaly, and disease-related symptoms, while XPO1 activity is important for malignant cell survival. By targeting these complementary pathways simultaneously, we believe selinexor has the potential to complement JAK inhibition and improve outcomes beyond symptom control alone. Turning to Slide 11, myelofibrosis remains a disease with a high unmet need given clinical activity with the currently approved therapies is modest.
As a result, spleen volume reduction of at least 35% is observed in less than a third of patients. Overall survival improvements are limited and meaningful modification of the underlying disease is not observed. Turning to Slide 12, a distinctive profile has been observed from the SENTRY trial. Given the compelling SVR35 results that are rapid, deep, and sustained, a promising OS signal, a first-of-a-kind prediction between SVR35 and OS, and a safe and manageable adverse event profile.
These data appear to support SVR35 as a reasonably likely surrogate endpoint, enabling an sNDA under the accelerated approval pathway. Turning to Slide 13, at Week 24 a nearly double spleen response rate was observed with the combination of selinexor plus ruxolitinib versus ruxolitinib alone. What is particularly important is the quality and kinetics of that response. As shown on Slide 14, the responses were rapid, emerging as early as Week 12, and deep, with greater average spleen volume reductions relative to baseline observed with the combination.
Both response rates and depth of response were sustained through Week 36. Importantly, as seen on Slide 15, the benefit was consistent across pre-specified patient subgroups, reinforcing the robustness of the treatment effect in the vast majority of frontline myelofibrosis patients. Especially important is a subgroup analysis by ruxolitinib dosing as seen on Slide 16. Even with average suboptimal doses of ruxolitinib less than 15 milligrams per day, SVR35 rates with the combination were as high as 50% compared to zero observed with ruxolitinib alone, indicating that with the combination SVR35 is driven by selinexor and supported by modest doses of ruxolitinib. From a clinical practice standpoint, these data suggest that ruxolitinib dose reductions may not compromise efficacy when combined with selinexor. As shown on Slide 17, at the time of the top-line analysis, the overall survival hazard ratio was 0.43, and patients continue to be followed as these data mature. On Slide 18, a post hoc landmark analysis demonstrated that irrespective of treatment, SVR35 at Week 24 predicted overall survival.
This observation is further reinforced by the longer-term follow-up from the Phase 1 trial on Slide 19, in which the same relationship between SVR35 and overall survival is observed. On Slide 20, the importance of the SVR35–OS relationship becomes even clearer when viewed in the context of the broader myelofibrosis literature. Over the past several years, a substantial body of retrospective evidence from Phase 3 JAK inhibitor trials has demonstrated that greater SVR35 rate differences observed across the two arms correlate with improved overall survival.
SENTRY now provides an important opportunity to build on that body of evidence as the first Phase 3 trial that prospectively demonstrates the same relationship and establishes SVR35 as a potential surrogate endpoint for overall survival. This underscores the importance of treating patients with the combination early in the disease course, increasing the likelihood an SVR35 reduction is observed, thus potentially maximizing overall survival. On Slide 21, we also observed higher rates of variant allele frequency reduction with selinexor plus ruxolitinib as early as Week 24.
These molecular findings are important because VAF reduction was associated with a greater likelihood of achieving SVR35, providing additional biological evidence that is consistent with the clinical findings. Taken together on Slide 22, the rapid, deep, and sustained spleen responses, the promising overall survival findings, the relationship between SVR35 and survival, and the molecular data all point in the same direction. We believe this unique and compelling profile strengthens the scientific rationale for SVR35 as a meaningful predictor of long-term survival.
It is the combination of this growing body of evidence, the strength of the SENTRY data, and the significant unmet need in myelofibrosis that form the basis of our scientific discussions with the FDA regarding the role of SVR35 in supporting our planned sNDA submission. We believe the FDA's written feedback indicating that SVR35 appears to qualify as a reasonably likely surrogate endpoint to predict overall survival represents an important scientific and regulatory milestone.
Importantly, this builds upon years of scientific evidence supporting the relationship between SVR35 and long-term outcomes, together with the prospective randomized evidence generated through SENTRY. Our planned submission will be based on the Week 24 SVR35 results. We intend to use additional long-term overall survival data from the ongoing SENTRY trial to verify clinical benefit, a requirement under the accelerated approval pathway to later convert to traditional approval.
While our immediate priority is our planned submission, we continue to explore the broader role of selinexor in myelofibrosis. On Slide 23, the ongoing Sentry 2 study provides an opportunity to further characterize the activity of selinexor as a monotherapy and explore the potential flexibility of XPO1 inhibition in combination with additional JAK inhibitors. The study will help us better understand the intrinsic contribution of selinexor and continue to define the broader role of XPO1 inhibition across the treatment of patients with myelofibrosis.
As Richard noted, we expect top-line data from the 60 milligram cohort of Sentry 2 during the second half of this year. Taken together, we believe the strength and consistency of the evidence generated through SENTRY, together with our continued clinical development efforts, provide a strong scientific foundation for our planned sNDA submission and reinforce our belief that selinexor has the potential to fundamentally change the treatment of patients with myelofibrosis.
With that, I'll turn the call over to Sohania.
Sahanya
Thank you, Reshma. Turning to Slide 25, my focus today is on why we believe Karyopharm Therapeutics is well positioned to commercialize this opportunity. Importantly, we're not preparing to build a commercial organization from the ground up. We're leveraging an established hematology platform that we have built over many years through the commercialization of XPOVIO. On the scientific side, we have clinical development experience, active medical and scientific affairs teams, investigative relationships and growing visibility across the myelofibrosis community.
On the commercial side, we have established coverage in both community and academic hematology, key account capabilities and market access expertise, and through KaryForward, we have an existing patient support platform designed to help patients and caregivers navigate access, reimbursement and treatment initiation. Importantly, these capabilities already work together to date in multiple myeloma and can now be leveraged to support the potential expansion of selinexor into myelofibrosis, which is a significant strategic advantage to enable a rapid and efficient launch.
Turning to Slide 26, Q2 was a breakout quarter with top-tier recognition across leading global oncology platforms. As Richard discussed, the SENTRY data have now been presented at ASCO and EHA, published in the Journal of Clinical Oncology, and continue to be highlighted at scientific meetings throughout the hematology community. Importantly, while commercial promotion begins only following regulatory approval, scientific engagement is already well underway.
Our medical and scientific affairs organization is already deeply engaged within the myelofibrosis community. Following ASCO and EHA, our medical and scientific affairs teams have continued scientific exchange with investigators and treating physicians, participated in regional educational programs and scientific symposia, and continued building upon the relationships established throughout the SENTRY clinical development program. We see significant engagement and thoughtful discussion surrounding the SENTRY results, particularly the rapid, deep and sustained spleen responses, the promising overall survival findings and the potential for disease modification. Furthermore, the structure of the myelofibrosis market is also well aligned with our existing footprint. As shown on Slide 27, approximately 70% of patients are treated in the community setting and 30% in academic centers. Across both settings, the majority of patients are concentrated within a manageable group of treatment centers. This concentration allows us to focus our resources on the physicians caring for the majority of patients and to deploy our existing organization efficiently.
Our physician segmentation work has also given us a detailed understanding of the high-volume, innovation-oriented physicians most likely to adopt a new combination approach early. These physicians place significant importance on achieving rapid, deep and sustained spleen responses and are actively considering how treatment may influence longer-term outcomes. There is also opportunity for prevalent patients treated with a JAK inhibitor to benefit from the combination therapy.
We hear physician interest in the ability of selinexor to maintain spleen responses even when ruxolitinib doses are reduced, which is clinically relevant given how frequently dose adjustments occur in practice. Finally, as we turn to Slide 28 and looking at the commercial opportunity in myelofibrosis, we believe selinexor plus ruxolitinib has the potential to generate up to approximately a billion in peak annual revenue in the U.S. alone. Approximately 20,000 patients are currently living with myelofibrosis in the U.S., with roughly 4,000 newly treated frontline patients each year, with no approved combination therapy in frontline myelofibrosis.
Let's now review our multiple myeloma performance, which continues to provide the commercial and operational foundation for the broader hematology platform I have described. As shown on Slide 30, we delivered another quarter of strong commercial execution with XPOVIO U.S. net product revenue of 30.8 million. Underlying demand remained relatively consistent with the second quarter of last year despite an increasingly competitive treatment landscape.
This performance reflects the resilience of our multiple myeloma franchise and, importantly, the strength of the relationships our commercial organization has built with hematologists and oncologists across both community and academic practices. Turning to Slide 31, we continue to believe XPOVIO is well positioned for sustained performance. Our focus remains on the community setting, which represents approximately 60% of our U.S. business, where physicians continue to value XPOVIO as a differentiated and convenient oral therapy.
In addition, XPOVIO continues to occupy a unique position in the evolving treatment landscape surrounding T‑cell–engaging therapies, providing physicians with flexibility both before a CAR T therapy and following progression on a T‑cell–engaging therapy. Our commercialization capabilities position us to continue to build on the foundation of multiple myeloma and, importantly, drive a transformative launch in the multibillion‑dollar myelofibrosis marketplace.
With that, I'll turn the call over to Laurie to review our financial results and discuss how our disciplined capital allocation strategy supports the opportunities ahead.
Laurie
Thank you, Sahanya, and good morning, everyone. Turning to Slide 33, I will focus on our second quarter financial performance, our financial outlook and the actions we're taking to support the important milestones Richard outlined. Starting with revenue, total revenue for the second quarter was 33.4 million compared to 37.9 million in the prior year period. The decrease reflects the conclusion of Menarini's reimbursement of development‑related expenses at the end of 2025, which reduced revenue by approximately $6.5 million compared with the prior year quarter.
U.S. XPOVIO net product revenue was $30.8 million compared to 29.7 million in the prior year period. Underlying demand remained consistent and our gross‑to‑net rate of 26.6% was comparable to the second quarter of 2025. Turning to expenses, we remain focused on disciplined execution. R&D expenses were 29 million and SG&A expenses were 25.9 million, down 12% and 9%, respectively, year over year. This reflects our continued prioritization, disciplined investment and focus on advancing our highest‑value late‑stage programs.
With our Phase 3 trials having completed enrollment, we also continue to maintain disciplined alignment of prelaunch investments with clinical and regulatory milestones. Net loss was $67 million for the quarter compared to $37.3 million in the prior year period. As a reminder, net loss includes non‑cash mark‑to‑market adjustments related to our financing structure. From an underlying operating perspective, performance improved with approximately an 8% reduction in loss from operations, reflecting stable net product revenue and continued expense discipline.
Turning to the balance sheet, we ended the quarter with $65.4 million in cash, cash equivalents, restricted cash and investments. Based on our current operating plan, we expect our existing liquidity, including cash, cash equivalents and investments, together with anticipated cash flow from net product revenue and license and other revenue, to fund our current operating plans into September 2026. As Richard discussed, we are actively evaluating a range of financing opportunities and strategic alternatives with the objective of extending our cash runway, preserving strategic flexibility and maximizing long‑term shareholder value as we advance our myelofibrosis program. On September 10, 2026, a $15.8 million principal payment is due under our senior secured term loan facility. If that payment is made without additional financing or a waiver from our lenders, we expect our cash, cash equivalents and investments will fall below our $10 million minimum liquidity covenant, which would constitute an event of default under the term loan. Importantly, our immediate priority is to address this and strengthen our financial position and provide the flexibility needed to continue executing our myelofibrosis strategy.
Every capital allocation decision we make is intended to support the important clinical, regulatory and commercial milestones ahead, while maintaining disciplined execution across our multiple myeloma business and maximizing long‑term value for patients and shareholders. Turning to guidance, we are reaffirming our full‑year 2026 outlook. We continue to expect total revenue in the range of $130 million to $150 million, its license and other revenue consisting entirely of royalties over the next two quarters, and U.S. XPOVIO net product revenue of 115 million to 130 million. We continue to expect combined R&D and SG&A expenses of 230 million to 245 million in 2026, excluding certain one‑time costs that we may incur associated with our endometrial cancer program and evaluating financing opportunities and/or strategic transactions. As a result of our decision to prioritize myelofibrosis and multiple myeloma, we are actively reducing investment across the endometrial cancer program and we expect our cost structure to decline over time.
A greater financial benefit will be realized in 2027 as we continue patient follow‑up for the near term and evaluate the evolving data set together with responsibly completing the remaining clinical and operational activities associated with the EC042 trial. In the near term, third quarter expenses may be modestly higher than the second quarter. This reflects a unique transition period for the company as we simultaneously advance our myelofibrosis program, implement the organizational changes associated with our decision to prioritize myelofibrosis and multiple myeloma following the EC042 top‑line results, and the costs we may incur to evaluate financing opportunities and strategic alternatives. With that, I will turn the call back over to Richard.
Richard (CEO)
Thank you. Before we open the call for questions, I'd like to leave you with one final thought. Karyopharm is entering one of the most important periods in our history. We have a compelling opportunity in myelofibrosis, a regulatory path forward, an experienced hematology organization prepared to support a potential launch if approved, and a team that has consistently demonstrated the ability to execute with focus, urgency and discipline. We also recognize the importance and urgency of this moment, and that is why we are acting with discipline not only in advancing our myelofibrosis program, but also in how we allocate capital and evaluate the financing opportunities and strategic alternatives discussed today. Every decision we make is guided by a single objective: maximizing long‑term value for patients and shareholders. I'd like to thank our employees for their extraordinary dedication, our investigators and collaborators for their partnership, and most importantly, the patients and families who have placed their trust in Karyopharm by participating in our clinical trials. We appreciate your continued support and look forward to updating you on our progress over the coming quarters.
And with that, operator, we'd now be pleased to take your questions.
OPERATOR (Operator)
Thank you. Ladies and gentlemen, we now begin the question and answer session. If you'd like to ask a question, please press star followed by the number one on your telephone keypad. We ask analysts to limit themselves to one question and a follow-up. If your question has been answered and you would like to withdraw from the queue, please press star followed by the number two. And if you're using a speakerphone, please lift your handset before pressing any keys.
One moment please. I will compile the roster. Your first question comes from Piper Sandler. Please go ahead.
Ted, Analyst at Piper Sandler
Great. Thank you very much. I just had some questions with respect to what still had to be done for the sNDA considering obviously selinexor is already approved in multiple myeloma. You know, how much of the filing is already done? And is there anything else that you need to compile on the clinical side? Any sites that need to be revisited, or does all that already seem to be taken care of with the current approval? Thank you, Tom.
Richard (CEO)
Yeah, thank you, Ted. I'll turn to Reshma to go into that in more detail.
Reshma
Yeah, thank you, Ted. And Richard. So Ted, you know, the team has actively been working on the sNDA. You know, by and large, you know, the vast majority has already been put together. It's ready to go. You know, one of the key pieces that we are just aligning and finalizing with the FDA is just around the confirmatory data piece. Right. So I think as we all appreciate, under accelerated approval, we are provided an approval, a label, but we do need to provide clinical benefit at some point in the future.
And so right now our discussions really have been focused on using the mature overall survival observed from SENTRY for finalizing the statistical analysis plans. Again, aligning on those last details, which is something that is required before we submit the sNDA. So great, productive conversations with the FDA. And we still are very much on track to submit the sNDA in August.
Ted, Analyst at Piper Sandler
That's really helpful just to make sure I understand. So you'll use the OS data from the ongoing SENTRY as the confirmatory data set?
Reshma
That is correct. Right. You know, we designed SENTRY intentionally from the very beginning to follow all the way for overall survival. So the study continues with patients, sites blinded. They continue on treatment, they continue to provide scans as well as OS data. So yes, we are going to leverage that maturing OS to confirm the benefit which is going to occur, you know, likely years from now. But that is going to serve as the confirmatory data set, we believe, you know, upon alignment with the FDA.
Ted, Analyst at Piper Sandler
That's really helpful. Thanks, Reshma. Good luck.
Richard (CEO)
Thank you. Appreciate it.
OPERATOR (Operator)
Thank you. Your next question comes from Yannis Orzidis with Cantor. Please go ahead.
Yannis Orzidis, Analyst at Cantor
Hey folks, appreciate the updates here. I guess just a quick question on kind of what is the right way to think about the feasibility here of future operations? Is accelerated approval absolutely needed or do you believe that inclusion in the NCCN compendia could provide sufficient revenues to address the debt and operating needs? And I have a quick follow-up.
Richard (CEO)
Yeah, thanks, Yanni. I think as we've talked to, there's really a few of those milestones happening very much in the near term. And obviously given that we're already an approved agent, NCCN is very important. And I think it's something which, as we know, physicians utilize a lot. And we've talked to that previously where, you know, with NCCN in similar situations, if NCCN is all that you achieve, usually products will achieve about 50% of what their peak may be.
But obviously our goal is to, you know, enable as broad access as possible. You know, one component is NCCN. The other component, as we've talked to, is really continuing to advance down the regulatory pathway. So, you know, I think both of those are occurring very, very positively over the near term. And I think both will be very positive for us in terms of, you know, being able to fund operations and obviously being able to enable patients to get access to selinexor and ruxolitinib in myelofibrosis.
Yannis Orzidis, Analyst at Cantor
Yeah, appreciate it. And then just I guess relatably too, you know, appreciate the transparency in kind of the upcoming payment required and the debt covenants there, I guess. Is there a sense of what would be kind of the stopgap in your kind of position the company well, financially from a liquidity perspective to make it through these near-term milestones and, you know, ideally I would imagine make it through at least first half or end of 2027.
Richard (CEO)
Yeah, I think, you know, as we've seen before, our lenders have consistently been very, very supportive with us and I don't have any reason to believe that they won't continue to do so. And so I think as we announced, we are working on a range of financing opportunities and strategic alternatives. We're in direct dialogue with our lenders with respect to these options. And I think obviously our goal is to work with lenders and potentially equity investors and find a way to, you know, enhance our clarity, extend the runway as we have these really important milestones, you know, in front of us in the second half of 2026.
So I think, you know, we'll be able to continue to execute on that and find the right balance as we move forward.
Yannis Orzidis, Analyst at Cantor
Understood. All right, thanks so much.
Richard (CEO)
Thanks, Yanni.
OPERATOR (Operator)
Thank you. Your next question comes from Brian Abrahams with RBC Capital Markets. Please go ahead.
Brian Abrahams, Analyst at RBC Capital Markets
Oh, hey, good morning. Thanks so much for taking my question and congrats on the continued progress. You mentioned in milestones the potential for inclusion of selinexor in the compendia in the back half of this year. That seems pretty rapid if the NCCN meeting is happening just this week. So I'm just curious if you're hearing anything emerging from the meeting that gives you confidence and maybe you could remind us of the process there. And then maybe just secondly, just curious if in your dialogue you're hearing any insights from the FDA on whether, prior to, and how open they might be to priority review.
Richard (CEO)
Sure. Thanks, Brian. I'll address the first part and I'll turn to Reshma for the second part. You know, obviously, you know, NCCN is an independent committee and an independent body. So, you know, they'll go through their process and evaluate. You know, importantly, we put the right components in place in terms of our ASCO presentation, our EHA presentation, our Journal of Clinical Oncology manuscript. I think all the right components are there. And, you know, we hear a high level of interest from, you know, opinion leaders to, you know, be able to get access to selinexor plus ruxolitinib.
So, you know, I think we're on track, as we said, to see that, you know, in the second half this year. And for the second part, I'll turn to Reshma to talk to the FDA.
Reshma
Yeah, thanks, Brian. So as I mentioned, really great, productive conversations with the FDA. In terms of priority review, not necessarily. So this is a request that we need to make with the FDA at the time that the application is submitted. They have approximately 60 days to review that request and then they'll provide that update shortly thereafter. So no, you know, specific insight, but we do believe that we have a strong package, potentially a, you know, a differentiating profile, you know, a need for a combination therapy.
So hopefully they will review it and, you know, expedite the PDUFA date that will enable an approval sometime early next year.
Brian Abrahams, Analyst at RBC Capital Markets
Super helpful. Thanks so much.
Richard (CEO)
Thanks, Brian.
OPERATOR (Operator)
Thank you. Your next question comes from Maury Raycraft with Jefferies. Please go ahead.
Maury Raycraft, Analyst at Jefferies
Hi. Thanks for taking my questions. Maybe I'll just ask one. On the term loan negotiations, Laurie, you mentioned potential for a waiver. What do those discussions look like and what could updated obligations look like if there's a waiver and what is the likelihood of that? Then I've got a follow-up question.
Richard (CEO)
Sure, maybe Maury, I'll address that one. I mean, just at a high level, you know, we're not going to obviously go into the details of the conversations and negotiations, but I think as we mentioned, you know, the lenders have been, you know, consistently supportive with us and again, I think we don't have any reason to believe that they won't continue to do so. So good, you know, productive conversations and working on the right solution as we move forward.
And obviously that's something that we're very focused on and working to achieve rapidly.
Maury Raycraft, Analyst at Jefferies
Understood. That's helpful. And then, and then for NCCN compendia listing, I guess what's your plan to get patients from your clinical studies onto paid drug and do you sense a proportion of patients from your studies that would make that switch early on with only the NCCN compendia listing?
Richard (CEO)
Well, I think on our study, as we mentioned, you know, we hope to see our study continue. Right. So our study continues. Patients are blinded, clinicians are blinded, we have a blinded study team inside Karyopharm. So, you know, we would look to see our study continue and I think as Reshma mentioned, we're looking to see that to be the confirmatory data from an accelerated approval perspective. So our focus would be to make sure we're really working with the sites, investigators, patients, etc., to continue patients on our Phase 3 program.
Maury Raycraft, Analyst at Jefferies
Understood. Okay, thanks for taking more questions.
Richard (CEO)
Thanks, Maury.
OPERATOR (Operator)
Thank you. Your next question comes from Michael King with Roadman and Rain Shop. Please go ahead.
Michael King, Analyst
Thanks. Good morning, guys. Thanks for taking the question. Just a little further granularity on the filing and the interaction with the FDA. I just [was] wondering, given the recent interaction with the B and C meetings and the updated analysis that you presented at ESMO, I just wonder if any part of the data set that you're going to submit could be considered to be a major amendment. Obviously this would be very impactful for the approval time.
So I'm just wondering how you're thinking about submitting the data to the agency.
Richard (CEO)
Yeah, let me turn to Reshma for that part.
Reshma
Yeah, thanks, Michael. Great question. So the sNDA, you know, under the accelerated approval is really going to be based upon the week 24 data. So the week 24 that we really believe is compelling and differentiating, of course, is going to be that SVR35 data, not only at week 24—that's the time point at which the primary analysis was conducted—but the kinetics really suggest something very differentiating. So of course that SVR35 at week 12, 24, 36 shows that sustained SVR.
Of course the overall survival data, the post hoc analysis with the relationship between SVR and OS, the disease modification data, and the safety. So that's the profile—again, very compelling at week 24—and again will form the basis for the sNDA.
Michael King, Analyst
Okay. And no 48-week data to be submitted then. Is that correct?
Reshma
That's correct. We're going to really focus on the week 24 data. Now there are some patients that have been followed for week 48. We'll provide that data as well. But the primary focus is really going to be on the week 24.
Michael King, Analyst
Okay. And can you say whether you'll include the prespecified OS confirmatory analysis in that submission?
Reshma
Yeah, absolutely. That's part of the differentiating package. And that OS data that we observed and of course presented at ASCO/EHA and was included in the JCO really was the basis for that post hoc analysis that allowed us to show that relationship between estimated SVR and OS. So it is a very important data point. Of course, we'll continue to follow patients on overall survival and, as mentioned earlier, we'll use those data to ultimately confirm the benefit in the future.
Michael King, Analyst
Great. Thanks for taking the questions.
Richard (CEO)
Thanks, Michael.
OPERATOR (Operator)
Thank you, Michael. There are no additional questions in the queue. I will turn it back to Richard for some closing remarks.
Richard (CEO)
Thank you, operator. And thank you everyone for joining us today and your continued interest in Karyopharm Therapeutics.
OPERATOR (Operator)
Ladies and gentlemen, this concludes your conference call for today. We thank you for participating and ask that you please disconnect your lines. Have a great day.
Disclaimer: This transcript is provided for informational purposes only. While we strive for accuracy, there may be errors or omissions in this automated transcription. For official company statements and financial information, please refer to the company's SEC filings and official press releases. Corporate participants' and analysts' statements reflect their views as of the date of this call and are subject to change without notice.
Login to comment